7 results about "Hyperphosphoremia" patented technology

The invention discloses a dietary compound containing resveratrol and application of the dietary compound in improvement of inflammatory injury of diabetic nephropathy, and belongs to the field of functional foods and dietary supplements. The L-WPI is taken as a carrier, so that the phosphorus load of a final product is reduced from the source, the problem that the hyperphosphatemia risk of a DKD patient is possibly aggravated by a conventional whey protein raw material is solved, and the L-WPI is more suitable for nutrition intervention of people with renal hypofunction. The L-WPI-Res compound constructed through heat treatment induction can effectively protect Res from being excessively degraded in a harsh stomach acidic and enzymatic hydrolysis environment, realizes stomach stability and intestinal targeted release, improves the biological accessibility of the compound in a small intestine stage by 20-35% compared with a free monomer, fundamentally solves the bottleneck problem of low oral availability of polyphenol compounds, and has a wide application prospect. Meanwhile, the L-WPI-Res-55 DEG C compound has a synergistic enhancement effect in two aspects of regulating blood sugar potential and relieving inflammation.

The invention belongs to the field of phosphate binders, and relates to a straight-chain saturated aliphatic dicarboxylic acid-iron (III) compound, a preparation method and application thereof, in particular to application of the straight-chain saturated aliphatic dicarboxylic acid-iron (III) compound in preparation of drugs for treating or preventing hyperphosphatemia. The molar ratio of iron element to dicarboxylic acid in the dicarboxylic acid-iron (III) compound is 1: (0.8-1.2), the dicarboxylic acid is straight-chain saturated aliphatic dicarboxylic acid, and the compound is prepared by reacting ferric salt and dicarboxylate in a solvent. An in-vitro phosphorus binding experiment proves that the dicarboxylic acid-iron (III) compound disclosed by the invention is high in phosphorus binding amount of iron per unit mass in a pH range of 3-7, can also keep very high phosphorus binding capacity of iron per unit mass in an animal body, and is obviously superior to commercially available sucrose iron oxyhydroxide chewable tablets. As an oral phosphorus binding agent, the compound disclosed by the invention is stronger in phosphorus binding capacity of unit mass of iron in vivo, high in iron utilization rate, small in total dosage of iron element and lower in adverse reaction.

The present application relates to the technical field of medicine and chemical industry, in particular to a kind of alginate / nano lanthanum hydroxide composite microspheres and its preparation method and application.The composite microspheres use sodium alginate as organic matrix material, and nano lanthanum hydroxide as inorganic filling phase, which are prepared by electrospray technology, and can realize the uniform dispersion and wrapping of nano lanthanum hydroxide in alginate microspheres.The size of the composite microspheres can be adjusted as needed between 235.5 μm and 748.4 μm, and the mass ratio of alginate to nano lanthanum hydroxide can be adjusted as needed within 1: (0.5-1.5).The composite microspheres of the present application have a phosphorus binding capacity of 41.0 mg / g-90.0 mg / g in a gastric acid environment with pH=2, and excellent phosphorus binding ability, which can be used as an oral phosphorus binding agent for the treatment of hyperphosphatemia, providing a new technical solution for clinical intervention of hyperphosphatemia.

Disclosed are peptide-fatty acid conjugates, pharmaceutical compositions containing them, and methods of their medical use in the treatment of, e.g., a disease or condition associated with the PTHR1 signaling overactivity (e.g., hypercalcemia, hypophosphatemia, hyperparathyroidism, or Jansen's metaphyseal chondrodysplasia) or deficiency (e.g., hypoparathyroidism, hyperphosphatemia, osteoporosis, fracture repair, osteomalacia, arthritis, thrombocytopenia, or chronic kidney disease).

The invention belongs to the technical field of formula foods for special medical purposes, and particularly relates to a low-potassium low-phosphorus protein component for special medical purposes and a preparation method thereof. The protein component is of a liquid ready-to-use type, and comprises the following components on the basis of 100 mL of total volume: 10.0-12.0 g of separated whey protein powder; and 0.05 to 0.15 g of stevioside. 0.20 to 0.30 g of a compound stabilizer; and the balance of water. The compound stabilizer is prepared from phospholipid and xanthan gum. The separated whey protein powder with low phosphorus and potassium content and specific calcium content is selected as a core protein source, so that the final product has extremely low phosphorus-protein ratio and potassium content. The phosphorus intake brought by the product is obviously lower than that of commercially available like products, and the kidney metabolism burden and the hyperphosphatemia risk of patients are greatly relieved. The phospholipid and the xanthan gum in a specific mass ratio are used as a compound stabilizer, and the phospholipid is used as an emulsifier, so that protein particles can be effectively wrapped, and aggregation is prevented.

The present disclosure relates to a pharmaceutical composition for providing phosphorus to an adult or pediatric patient, wherein the composition is an aqueous solution of sodium glycerophosphate which by virtue of an improved process for producing the active pharmaceutical ingredient and the pharmaceutical composition is characterized by a low amount of free phosphate, a low amount of SGP-related substances and by a low amount of aluminum. The pharmaceutical composition is used in clinical nutrition, preferably in the preparation of nutritional formulations by compounding. The compositions can further be used for preventing or correcting phosphorus deficiency (hyperphosphatemia) in said adult or pediatric patients.

The present invention provides a metal-organic framework (MOF) that finds utility in the treatment or prevention of hyperphosphatemia, wherein the MOF comprises a plurality of metal ions, each coordinated to a plurality of organic ligands, and wherein the plurality of metal ions comprises Zr4+ ions, Fe3+ ions, or a combination of Zr4+ and Fe3+ ions, and the plurality of organic ligands are selected from one or more members of the group consisting of a compound according to formula (I) as defined herein; a C2-6alkane substituted by two carboxylate groups and optionally substituted by one or two OH groups; a C4-6alkene substituted by two carboxylate groups; a benzenedicarboxylate optionally substituted by one or two NH2 groups; a benzenetricarboxylate; a 5-6 membered heteroaromatic ring comprising 1 or 2 atoms selected from the group consisting of N, S and O, wherein said heteroaromatic ring is substituted by two carboxylate groups; cyclohexane substituted by two carboxylate groups; and cystinate; or a pharmaceutically acceptable salt or solvate thereof. The present invention also provides a pharmaceutical composition comprising a MOF of the present invention.